Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects
Table 1
Postulated TIE2 in vivo inhibition based on clinical TKI dosing and tested models.
To understand the relevance of TIE2 inhibition, observed and reported TKI levels in retina/choroid of pre-clinical in vivo models treated with a clinical dosage of the TKIs were analyzed. The observed/reported TKI information in this table was extrapolated from the indicated references, which are publicly available presentations/publications, and that information did not provide statistical data. TIE2 IC50 values for each TKI were determined by Reaction Biology (US) and shown in Fig 3B.